Pipeline

MeMed’s expertise lies in the convergence of biochemistry, medicine, machine learning and bioinformatics. By identifying and measuring biomarkers that are key players in the body’s response to a disease, and then integrating those measurements through the application of machine learning algorithms, we can offer clinicians straightforward and actionable tools that help them provide better care to their patients. Following the commercialization of MeMed BV^® and MeMed COVID-19 Severity^™, we’re now developing the following products.

The question surrounding a patient’s likelihood of deterioration involves high uncertainty and poses a real challenge to clinicians. MeMed Universal Severity is designed to provide clinicians with an actionable result that helps assess the likelihood of deterioration in patients with suspected acute infection.

MeMed Universal Severity has been developed and studied successfully in medical centers in the US and Israel, and is expected to offer tangible benefits to patients, clinicians and the healthcare system at-large including:

• Improved patient outcomes by early and accurate detection of severe disease and provision of prompt personalized treatment.
• Decreased clinical workload through appropriate risk stratification and patient management and reduction in the emergency department.
• Cost savings from improved resource allocation, more accurate patient dispositioning, and reduced readmissions.